$BPTH
BIO-PATH HOLDINGS, INC.

2023 Q3 Form 10-Q Financial Statement

#000155837023014847 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $980.0K $1.191M
YoY Change -17.85% 2.76%
% of Gross Profit
Research & Development $2.292M $3.051M
YoY Change -2.59% 64.83%
% of Gross Profit
Depreciation & Amortization $30.00K $22.00K
YoY Change 36.36% 4.76%
% of Gross Profit
Operating Expenses $3.276M $4.242M
YoY Change -7.61% 40.93%
Operating Profit -$3.276M -$4.242M
YoY Change -7.61% 40.93%
Interest Expense $10.00K $8.000K
YoY Change -9.09% 300.0%
% of Operating Profit
Other Income/Expense, Net $77.00K $8.000K
YoY Change 600.0% 300.0%
Pretax Income -$3.200M -$4.234M
YoY Change -9.48% 40.76%
Income Tax
% Of Pretax Income
Net Earnings -$3.199M -$4.234M
YoY Change -9.5% 40.76%
Net Earnings / Revenue
Basic Earnings Per Share -$0.32 -$0.53
Diluted Earnings Per Share -$0.32 -$0.53
COMMON SHARES
Basic Shares Outstanding 11.46M 7.960M
Diluted Shares Outstanding 10.05M 7.960M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.350M $3.444M
YoY Change -82.78% -79.77%
Cash & Equivalents $2.352M $3.444M
Short-Term Investments
Other Short-Term Assets $1.800M $1.746M
YoY Change -15.89% 25.43%
Inventory
Prepaid Expenses $632.0K $1.069M
Receivables
Other Receivables
Total Short-Term Assets $4.802M $6.259M
YoY Change -73.52% -69.56%
LONG-TERM ASSETS
Property, Plant & Equipment $92.00K $114.0K
YoY Change -49.17% -43.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $219.0K $265.0K
YoY Change -45.52% -40.58%
TOTAL ASSETS
Total Short-Term Assets $4.802M $6.259M
Total Long-Term Assets $219.0K $265.0K
Total Assets $5.021M $6.524M
YoY Change -72.92% -68.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $300.0K $638.0K
YoY Change -70.0% 6.33%
Accrued Expenses $1.000M $675.0K
YoY Change -9.09% 12.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.357M $1.426M
YoY Change -38.35% 7.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.140M $55.00K
YoY Change 708.51% -67.26%
Total Long-Term Liabilities $1.140M $55.00K
YoY Change 708.51% -67.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.357M $1.426M
Total Long-Term Liabilities $1.140M $55.00K
Total Liabilities $2.496M $1.481M
YoY Change 6.58% -0.54%
SHAREHOLDERS EQUITY
Retained Earnings -$104.2M -$101.0M
YoY Change 19.04% 20.24%
Common Stock $11.00K $8.000K
YoY Change 57.14% 14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.500M $5.043M
YoY Change
Total Liabilities & Shareholders Equity $5.021M $6.524M
YoY Change -72.92% -68.95%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.199M -$4.234M
YoY Change -9.5% 40.76%
Depreciation, Depletion And Amortization $30.00K $22.00K
YoY Change 36.36% 4.76%
Cash From Operating Activities -$2.780M -$3.287M
YoY Change -17.61% -21.79%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.690M
YoY Change
NET CHANGE
Cash From Operating Activities -2.780M -3.287M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 1.690M
Net Change In Cash -1.090M -3.287M
YoY Change -67.69% -22.18%
FREE CASH FLOW
Cash From Operating Activities -$2.780M -$3.287M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$2.780M -$3.287M
YoY Change -17.61% -21.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7960000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7160000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7960000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7160000
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7960000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7960000
dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
dei Entity Central Index Key
EntityCentralIndexKey
0001133818
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36333
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
dei City Area Code
CityAreaCode
832
dei Local Phone Number
LocalPhoneNumber
742-1357
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BPTH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11460164
CY2023Q2 us-gaap Cash
Cash
3444000
CY2022Q4 us-gaap Cash
Cash
10384000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1069000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3587000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1746000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1644000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
6259000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
15615000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1006000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
962000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
114000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
158000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
151000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2023Q2 us-gaap Assets
Assets
6524000
CY2022Q4 us-gaap Assets
Assets
15971000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
638000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
667000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
675000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
909000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
113000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1426000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1684000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
55000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113000
CY2023Q2 us-gaap Liabilities
Liabilities
1481000
CY2022Q4 us-gaap Liabilities
Liabilities
1797000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7960000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7960000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
106071000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105695000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101036000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91529000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5043000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14174000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6524000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15971000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3051000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1851000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7040000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3949000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1191000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1159000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2494000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2420000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4242000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3010000
us-gaap Operating Expenses
OperatingExpenses
9534000
us-gaap Operating Expenses
OperatingExpenses
6369000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4242000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3010000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9534000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6369000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
us-gaap Investment Income Interest
InvestmentIncomeInterest
27000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
27000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4234000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3008000
us-gaap Net Income Loss
NetIncomeLoss
-9507000
us-gaap Net Income Loss
NetIncomeLoss
-6367000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7960000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7160000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7960000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7160000
us-gaap Net Income Loss
NetIncomeLoss
-9507000
us-gaap Net Income Loss
NetIncomeLoss
-6367000
us-gaap Share Based Compensation
ShareBasedCompensation
376000
us-gaap Share Based Compensation
ShareBasedCompensation
430000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
47000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
45000
us-gaap Depreciation
Depreciation
44000
us-gaap Depreciation
Depreciation
43000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2518000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1624000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
102000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-451000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-263000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
343000
bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
53000
bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
50000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6940000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6729000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6940000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6750000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10384000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23774000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3444000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17024000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
85000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
22315000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
213000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3008000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
19520000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9107000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
170000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4234000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5043000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25457000
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
430000
us-gaap Net Income Loss
NetIncomeLoss
-6367000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
19520000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14174000
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
376000
us-gaap Net Income Loss
NetIncomeLoss
-9507000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5043000
CY2023Q2 us-gaap Cash
Cash
3400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0243
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.27
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3600000
CY2023Q2 bpth Expected Advanced Payment To Be Expensed
ExpectedAdvancedPaymentToBeExpensed
1100000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0342
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
658000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
221000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.39
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
879000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.09
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
822000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.23
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
428000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.18
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
100000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1200000
bpth Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndUnvestedWeightedAverageRemainingContractualTerm
P2Y1M6D
CY2023Q2 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
1700000

Files In Submission

Name View Source Status
0001558370-23-014847-index-headers.html Edgar Link pending
0001558370-23-014847-index.html Edgar Link pending
0001558370-23-014847.txt Edgar Link pending
0001558370-23-014847-xbrl.zip Edgar Link pending
bpth-20230630.xsd Edgar Link pending
bpth-20230630x10q.htm Edgar Link pending
bpth-20230630xex31.htm Edgar Link pending
bpth-20230630xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
bpth-20230630_pre.xml Edgar Link unprocessable
bpth-20230630_cal.xml Edgar Link unprocessable
bpth-20230630_lab.xml Edgar Link unprocessable
bpth-20230630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bpth-20230630x10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending